

Nottingham Breast Pathology Masterclass

21 & 22 July 2015

Tuesday 21st July 2015

Theme of the Day: Challenging Breast Lesions

Time	Speaker	Topic
08.30	Dr Emad Rakha/ Professor Ian Ellis	Registration and coffee
09.00		Welcome
09.10	Dr Andrew Lee	Immunohistochemistry in breast pathology: when does it help? applications and challenges
09.50		Discussion
09.55	Professor Sarah Pinder	Challenging breast lesions: Proliferative breast lesions: Hyperplasia; usual and atypical, columnar cell change and flat epithelial atypia, lobular neoplasia and carcinoma in-situ
10.25		Discussion and Tea
10.45		Slide seminar
12.00	Professor Vincenzo Eusebi	Challenging breast lesions: Spindle cell lesions
12.25		Discussion
12.30	Dr Emad Rakha	Challenging breast lesions: papillary lesions
12.55		Discussion
13.00		Lunch
13.45		Slide seminar
15.00	Dr Andrew Lee	Challenging breast lesions: Fibroepithelial lesions
15.25		Discussion
15.30	Professor Vincenzo Eusebi	Challenging breast lesions: Uncommon but tricky breast lesions
16.00		Discussion and Tea
16.15	Professor Ian Ellis/Dr Zsolt Hodi	My most challenging breast case
16.45		Discussion
16.50	Professor Ian Ellis/ Professor Vincenzo Eusebi/Professor Sarah Pinder/Dr Emad	Meet the expert – question and answer session

	Rakha	
17.20	Dr Emad Rakha	Slide seminar - Discussion of cases (continued)
17.45		Close
19.00		Course Dinner:

Wednesday 22nd July

Theme of the Day: Keys Issues of Clinical Relevance in Breast Pathology

Time	Speaker	Topic
08.30	Professor Ian Ellis/Dr Emad Rakha	National breast pathology EQA: performance issues
09.00	Professor Sami Shousha/Dr Andrew Lee/Dr Abeer Shaaban/Dr Jeremy Thomas	Session 1 Keys Issues of Clinical Relevance in Breast Pathology*
10.30		Coffee and Tea Break
11.00	Professor Ian Ellis/Professor Sarah Pinder/ Professor Sami Shousha/ Dr Elena Provenzano/ Dr Abeer Shaaban	Session 2 Keys Issues of Clinical Relevance in Breast Pathology**
12.30		Lunch
13.20	Professor Ian Ellis/Professor Sarah Pinder/Dr Jeremy Thomas/Dr Emad Rakha/ Dr Abeer Shaaban	Session 3 Keys Issues of Clinical Relevance in Breast Pathology***
14.50		Slide seminar
16.00		Coffee and Tea Break
16.20	Roche	An update on the prognostic and predictive factors in breast cancer
17.00		Close

* Session1:

- Impact of differentiation between isolated tumour cells and micromets in LN (also extracapsular invasion and its role in axillary radiotherapy: should we assess it?)
- Impact of differentiation between unifocal and multifocal disease and difference in size measurement in both scenarios.
- Margin Assessment including what define complete excision, anterior and posterior margin assessment in WLE specimens, margins assessment in mastectomy specimens including skin sparing: The surgical guidelines have changed now and it is worth making pathologists aware of this and discussing current practice.
- What defines a positive margin in routine practice? To include impact of atypical ducts (atypical isolated ducts at margins as either ADH or part of index DCIS in malignant cases) or foci of LVI near surgical margins. Significance of differentiating LCIS from PLCIS at margins.
- What is the importance between complete pathological response and minimal residual disease in the breast, (ie do we need IHC? Does it make a difference...).
- Tricky issue of clinical relevance: in situ versus invasion and benign versus malignant.

** Session2:

- Lobular versus ductal breast lesions, is it important? SEP to lead
- How to report LCIS with necrosis and PLCIS (in NCB, at margin and impact on size measurement).
- Impact of tumour typing on core biopsy and on excision. Why bother?
- Problematic core biopsy categorisation: B1Vs B2 and the use of B4 and B5c.
- Tumour cell displacement at biopsy site and in papillary lesion (benign and malignant) and its impact on size and margin status.
- How can we deal with cases showing possible LVI on H&E and use of IHC in routine practice?

*** Session3:

- How consistent are you in reporting – lessons from the national breast pathology EQA scheme.
- How do you resolve a case which is difficult to grade (1 or 2, 2 or 3) and issues with grading of DCIS.
- Oestrogen receptor and HER2 assessment in routine practice: challenging issues and impact of guidelines update.
- Breast specimens handling: Guidelines and approaches.

- What is important in handling post neoadjuvant therapy treated cases (specimen examination and reporting).
- Dealing with recurrent cases. How to differentiate recurrent from new primaries and its clinical significance?

Please note this programme is subject to minor changes!